TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02750020

Intervention type: OTHER
Intervention: Questionnaire
Description: Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.

Intervention type: OTHER
Intervention: Questionnaire
Description: Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.

Intervention type: OTHER
Intervention: Questionnaire
Description: Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
Study: NCT00747357

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon SeQuent Please
Description: Drug Eluting Balloon is followed by Bare Metal Stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Drug Eluting Balloon SeQuent Please
Description: Bare Metal Stent followed by Drug Eluting Balloon
Study: NCT02141737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride Injection
Description: Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride Injection
Description: Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride Injection
Description: Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Etomidate Fat Emulsion Injection
Description: 1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate Fat Emulsion Injection
Description: 1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate Fat Emulsion Injection
Description: 1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etomidate Fat Emulsion Injection
Description: 1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: 2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: normal saline
Description: 2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
Study: NCT01777152

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: 750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
Study: NCT02141737

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Midazolam Injection
Description: 0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Injection
Description: 0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Injection
Description: 0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
Study: NCT04491656

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: WALANT Technique
Description: A technique commonly used in hand surgeries where the combination of lidocaine and epinephrine is used for local blood control, thus performing the procedure without a tourniquet
Study: NCT02141737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam Injection
Description: 0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl Citrate Injection
Description: 3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
Study: NCT03264430

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: an antagonist of the NMDA receptor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: bupivacaine
Description: local anaesthetic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: local anaesthetic
Study: NCT01956812

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMMU-107
Description: Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine, 200 mg/m2, given weekly x 4 in both arms

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
Study: NCT01991132

Intervention type: OTHER
Group type: OTHER
Intervention: MediView 2.0 software
Study: NCT02580500

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: epidural catheter
Description: epidural anaesthesia application for spinal catheter will be used

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spinal catheter
Description: spinal anesthesia application for spinal catheter will be used
Study: NCT02141737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Injection
Description: 3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Injection
Description: 3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl Citrate Injection
Description: 3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rocuronium Injection
Description: 0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Injection
Description: 0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Injection
Description: 0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rocuronium Injection
Description: 0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
Study: NCT01689493

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: patient education and daily SMS
Description: The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
Study: NCT02916537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTT1057
Description: Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prostatectomy
Description: Radical prostatectomy with lymph node dissection
Study: NCT01136785

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active CPAP Therapy
Description: 7 days of active CPAP therapy

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham CPAP therapy
Description: 7 days of sham CPAP therapy
Study: NCT04554121

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brain Basics
Description: Computer-based exercises targeting impairments in cognitive domains (sensory processing, processing speed, attention, working memory, memory) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday.~life.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brain Training
Description: Computer-based exercises targeting impairments in cognitive domains (processing speed, attention, working memory, executive functions) are paired with verbal discussions and group-based activities to strengthen metacognition and to bridge newly learned cognitive skills to everyday life.
Study: NCT03039946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Closed-Loop GDFT
Description: Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Restrictive Fluid Therapy
Description: Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
Study: NCT00666484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study: NCT06771635

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: concurrent
Description: The concurrent training program is divided into three types of training: endurance, cardiovascular and neuromotor.~Resistance training sessions were performed in a circuit format with \>30 rest periods between exercises. The volume of work ranged from 8 to 12 repetitions at 60% of the estimated 1 maximum repetition (RM).~The cardiovascular work time per session ranged from 25-50 min depending on the intensity of the exercise and the intensity was regulated according to the maximum heart rate (FHR) estimated for each subject between 60-75%~The neuromotor training intensity of the sessions was low. The participants wore a heart rate monitor and were instructed not to exceed 60% of their HRF

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: Non training intervention
Study: NCT00666484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study: NCT03035877

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multisystemic Therapy-Emerging Adults
Description: MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Treatment as Usual
Description: With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
Study: NCT04164511

Intervention type: DIETARY_SUPPLEMENT
Intervention: 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)
Description: The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.

Intervention type: DIETARY_SUPPLEMENT
Intervention: 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy)
Description: The patients will receive 2 daily standard doses of vanilla-chocolate ice cream (cryotherapy) for 2 weeks post-op, with amount of analgesic consumption and subjective pain levels recorded on a VAS scale.
Study: NCT00738478

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nasogastric tube
Description: insertion of nasogastric tube for 2 days after operation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: without nasogastric tube
Description: without nasogastric tube after operation
Study: NCT03581851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude: (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Simulated Altitude: (FiO2: 15.1)
Description: Inhalation of deoxygenated air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study: NCT04321447

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical practice guideline for prevention and management of extravasation injury
Description: Implementation of an evidence-based clinical practice guideline and delivery of an educational programme for nurses
Study: NCT02070198

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Long acting FSH and GnRH antagonist
Description: Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daily FSH and GnRH antagonist
Description: Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin and recombinant FSH
Description: Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
Study: NCT03581851

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shamed Hypoxia (FiO2: 20.9)
Description: Inhalation of unmodified air through an altitude simulator (Altitrainer) for approximately 1 hour given by a facemask.
Study: NCT02652884

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phosphate and betamethasone acetate, 2 mL.
Description: single dose of intramuscular depot corticosteroid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline 0.9% NaCl
Description: single dose of intramuscular placebo
Study: NCT02005757

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bredinin tablet 150mg
Description: Bredinin 150mg qd vs Bredinin 50mg tid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bredinin tablet 50mg
Description: Bredinin 150mg qd vs Bredinin 50mg tid
Study: NCT01707407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg pomalidomide capsule administered orally once in the morning

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4 mg pomalidomide capsule administered orally once in the morning
Study: NCT01232803

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir 1% gel
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2% N-9 gel
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC Placebo gel
Description: Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
Study: NCT01683097

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standardized explanation
Description: Standardized explanation provided on code status, advance directives and end of life care
Study: NCT02756806

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Picosecond Q-switched laser
Description: Each subject will receive laser treatments with Enlighten laser
Study: NCT04565743

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Support on dentification and treatment of patients with high risk of osteoporotic fractures
Description: Education for primary care health care professionals and referral of patients with recent osteoporotic fracture.
Study: NCT01806701

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy
Description: the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
Study: NCT05605938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoten for children
Description: Oral administration

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration
Study: NCT03307655

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control (fertile semen donors)
Description: The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patients (subfertile men)
Description: The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.~Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined.
Study: NCT00660686

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: 60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility Training
Description: 60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.